Floatz Rating
B59/100
Confidence
Indicative
Sponsor
University of California, San Francisco
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04598009CT.gov Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma | — | Recruiting | — | — | — |
NCT05274438CT.gov Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut | — | Unknown | — | — | — |
NCT04546074CT.gov Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma | — | Unknown | — | — | — |
NCT02812693CT.gov Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification | — | Withdrawn | — | — | — |
NCT01738139CT.gov Ipilimumab and Imatinib Mesylate in Advanced Cancer | — | Completed | — | — | — |
NCT01782508CT.gov A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma | — | Unknown | — | — | — |
NCT00470470CT.gov Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT00424515CT.gov Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma | — | Completed | — | — | — |
NCT00421317CT.gov Imatinib in Adult Patients With Metastatic Ocular Melanoma | — | Terminated | — | — | — |
NCT00074308CT.gov Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers | — | Completed | — | — | — |
Show 1 more trialShow fewer
NCT00027586CT.gov Imatinib Mesylate in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Imatinib (this asset) | University of California, San Francisco | P2 | B · 59 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Sargramostim | Mayo Clinic | P3 | BBB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Temsirolimus | University of Regensburg | P2 | BB |
| Tebentafusp | Immunocore Ltd | P3 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
+42 more in the Melanoma cohort
Other indications for Imatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | — | P2 | BB · 71 |
| Chronic Myeloid Leukemia | — | P2 | BB · 71 |
| B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Imatinib in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/imatinib-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →